Growing the love for investing
Results 1 - 10 of 47 : 1 2 3 4 5 Next
Alkermes Beats Up on Analysts Yet Again
Just the facts, Fool.
Will Bydureon Gain FDA Approval?
Get out your crystal ball.
3 Stock-Moving Binary Events to Watch in 2012
A look at what's coming up in biotech.
Byetta Breakup! Buying Opportunity?
We all saw this coming.
4-Star Stocks Poised to Pop: Alkermes
Market-trouncing returns could be written in this four-star.
Let's Just Hope For No More FDA Surprises
Despite the government's worries, Bydureon doesn't cause heart issues.
Amylin, Alkermes Once-Weekly Diabetes Drug Passes Heart Trial
What does this mean for the drug companies?
In Biotech, Two Platforms Are Better Than One
Alkermes buys Elan Drug Technology.
Fewer Needle Pricks for the Europeans
Bydureon gets a positive recommendation in Europe.
Amylin, Alkermes Shares Jump as EU Regulators Recommend Diabetes Drug
Will this drug be approved in Europe?
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK